Men suffering from category III chronic prostatitis may benefit from N-acetylcysteine as an adjunct to alpha-blockers

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY LUTS: Lower Urinary Tract Symptoms Pub Date : 2022-01-23 DOI:10.1111/luts.12425

Amir-mohammad Yaryari, Seyed Habibollah Mousavibahar, Shahriar Amirhassani, Maryam Bagheri, Younes Mohammadi, Maryam Mehrpooya

{"title":"Men suffering from category III chronic prostatitis may benefit from N-acetylcysteine as an adjunct to alpha-blockers","authors":"Amir-mohammad Yaryari, Seyed Habibollah Mousavibahar, Shahriar Amirhassani, Maryam Bagheri, Younes Mohammadi, Maryam Mehrpooya","doi":"10.1111/luts.12425","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>We designed this study to investigate the potential use of N-acetylcysteine (NAC) as an adjunct to alpha-blockers in the treatment of category III chronic prostatitis (CP).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Sixty-three men with category III CP with a National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score of 15 or more were randomized to either the NAC treatment group or the placebo treatment group. Besides tamsulosin at a dose of 0.4 mg once daily, participants based on their allocation group received NAC or placebo at a dose of 600 mg twice daily for 12 weeks. The efficacy of the medications was assessed by measuring changes in the NIH-CPSI total score and its subscales, including pain, urinary symptoms, and quality of life.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Based on the general linear model analysis of the data, over the 12-week treatment, NAC+tamsulosin was statistically superior to placebo+tamsulosin in reducing the total NIH-CPSI score, pain subscore, and quality-of-life subscore (<i>P</i> value <.001). Further, after 12 weeks, more patients in the NAC+tamsulosin group than in the placebo+tamsulosin group met the responder criterion, defined as a decrease of at least 6 points in the NIH-CPSI total score (65.6% vs 29.0%). A more favorable outcome was also noted in the NAC+tamsulosin group regarding the number of patients reporting moderate or marked improvement in symptoms (62.5% vs 25.80%). No significant difference was seen between the groups concerning changes in urinary symptoms.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our study provided clinical evidence that men with category III CP might benefit from NAC treatment. Further studies are needed for the validation of these findings.</p>\n </section>\n </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"LUTS: Lower Urinary Tract Symptoms","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/luts.12425","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Objective

We designed this study to investigate the potential use of N-acetylcysteine (NAC) as an adjunct to alpha-blockers in the treatment of category III chronic prostatitis (CP).

Methods

Sixty-three men with category III CP with a National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score of 15 or more were randomized to either the NAC treatment group or the placebo treatment group. Besides tamsulosin at a dose of 0.4 mg once daily, participants based on their allocation group received NAC or placebo at a dose of 600 mg twice daily for 12 weeks. The efficacy of the medications was assessed by measuring changes in the NIH-CPSI total score and its subscales, including pain, urinary symptoms, and quality of life.

Results

Based on the general linear model analysis of the data, over the 12-week treatment, NAC+tamsulosin was statistically superior to placebo+tamsulosin in reducing the total NIH-CPSI score, pain subscore, and quality-of-life subscore (P value <.001). Further, after 12 weeks, more patients in the NAC+tamsulosin group than in the placebo+tamsulosin group met the responder criterion, defined as a decrease of at least 6 points in the NIH-CPSI total score (65.6% vs 29.0%). A more favorable outcome was also noted in the NAC+tamsulosin group regarding the number of patients reporting moderate or marked improvement in symptoms (62.5% vs 25.80%). No significant difference was seen between the groups concerning changes in urinary symptoms.

Conclusions

Our study provided clinical evidence that men with category III CP might benefit from NAC treatment. Further studies are needed for the validation of these findings.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

患有III类慢性前列腺炎的男性可能受益于n -乙酰半胱氨酸作为α受体阻滞剂的辅助药物

目的:研究n -乙酰半胱氨酸(NAC)作为α受体阻滞剂辅助治疗III类慢性前列腺炎(CP)的潜在应用价值。方法将63例美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)总分在15分及以上的III型CP患者随机分为NAC治疗组和安慰剂治疗组。除了每天一次0.4毫克的坦索罗辛外，根据他们的分配组，参与者接受了每天两次600毫克剂量的NAC或安慰剂，持续12周。通过测量NIH-CPSI总分及其亚量表(包括疼痛、泌尿系统症状和生活质量)的变化来评估药物的疗效。结果根据数据的一般线性模型分析，在12周的治疗期间，NAC+坦索罗辛在降低NIH-CPSI总评分、疼痛评分和生活质量评分方面具有统计学上的优势(P值< 0.001)。此外，12周后，NAC+坦索罗辛组比安慰剂+坦索罗辛组有更多的患者符合应答标准，定义为NIH-CPSI总分下降至少6分(65.6% vs 29.0%)。在NAC+坦索罗辛组中，报告症状中度或显著改善的患者人数(62.5% vs 25.80%)也出现了更有利的结果。在泌尿系统症状的改变方面，两组之间没有明显差异。结论我们的研究提供了临床证据，表明III型CP患者可能从NAC治疗中获益。需要进一步的研究来验证这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

LUTS: Lower Urinary Tract Symptoms UROLOGY & NEPHROLOGY-

CiteScore

3.00

自引率

7.70%

发文量

审稿时长

>12 weeks

期刊介绍： LUTS is designed for the timely communication of peer-reviewed studies which provides new clinical and basic science information to physicians and researchers in the field of neurourology, urodynamics and urogynecology. Contributions are reviewed and selected by a group of distinguished referees from around the world, some of whom constitute the journal''s Editorial Board. The journal covers both basic and clinical research on lower urinary tract dysfunctions (LUTD), such as overactive bladder (OAB), detrusor underactivity, benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), urinary incontinence, pelvic organ prolapse (POP), painful bladder syndrome (PBS), as well as on other relevant conditions. Case reports are published only if new findings are provided. LUTS is an official journal of the Japanese Continence Society, the Korean Continence Society, and the Taiwanese Continence Society. Submission of papers from all countries are welcome. LUTS has been accepted into Science Citation Index Expanded (SCIE) with a 2011 Impact Factor.